Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

Specimen Handling 122pembrolizumab 118Magnetic Resonance Spectroscopy 107Carboplatin 86Cyclophosphamide 75Biopsy 68Cisplatin 63Paclitaxel 58Bevacizumab 56Gemcitabine 49Nivolumab 47fludarabine 44Dexamethasone 39Rituximab 38Pemetrexed 38Fluorouracil 37atezolizumab 36Docetaxel 36Doxorubicin 34Radiotherapy 33Leucovorin 33venetoclax 31Oxaliplatin 30Capecitabine 30Temozolomide 28Prednisone 28Standard of Care 27Radiation 27Letrozole 27Cetuximab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × BCG Vaccine × 30 days × Clear all
NCT06833073 2026-05-28

INTerpath-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
308 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡